<code id='AE92BF91EE'></code><style id='AE92BF91EE'></style>
    • <acronym id='AE92BF91EE'></acronym>
      <center id='AE92BF91EE'><center id='AE92BF91EE'><tfoot id='AE92BF91EE'></tfoot></center><abbr id='AE92BF91EE'><dir id='AE92BF91EE'><tfoot id='AE92BF91EE'></tfoot><noframes id='AE92BF91EE'>

    • <optgroup id='AE92BF91EE'><strike id='AE92BF91EE'><sup id='AE92BF91EE'></sup></strike><code id='AE92BF91EE'></code></optgroup>
        1. <b id='AE92BF91EE'><label id='AE92BF91EE'><select id='AE92BF91EE'><dt id='AE92BF91EE'><span id='AE92BF91EE'></span></dt></select></label></b><u id='AE92BF91EE'></u>
          <i id='AE92BF91EE'><strike id='AE92BF91EE'><tt id='AE92BF91EE'><pre id='AE92BF91EE'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:comprehensive    - browse:48
          Illustration of two DNA strands made of banknotes. -- health coverage from STAT
          Adobe

          The staff of the Institute for Clinical and Economic Review, or ICER, are known as the nerds of the drug industry: bespectacled killjoys who emerge a few times a year to scold drugmakers for pricing their latest cancer or MS advance far beyond reason.

          But last year, they sat down and concluded a forthcoming treatment was worth up to $3.9 million — more than any medicine in history, more than a 45-year supply of Humira, the autoimmune drug often held up as an emblem of America’s runaway drug spending. 

          advertisement

          It was a testament to the power of a new class of gene therapies to deliver something pharma so rarely does: Genuine cures. The treatment, approved last week as Lenmeldy, may allow some babies born with an ultra-rare neurodegenerative disease called metachromatic leukodystrophy, or MLD, to grow up and live essentially normal lives.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus